VISUDYNE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Visudyne, and what generic alternatives are available?
Visudyne is a drug marketed by Bausch Lomb Ireland and is included in one NDA.
The generic ingredient in VISUDYNE is verteporfin. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the verteporfin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VISUDYNE?
- What are the global sales for VISUDYNE?
- What is Average Wholesale Price for VISUDYNE?
Summary for VISUDYNE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Clinical Trials: | 57 |
| Patent Applications: | 7,316 |
| Drug Prices: | Drug price information for VISUDYNE |
| What excipients (inactive ingredients) are in VISUDYNE? | VISUDYNE excipients list |
| DailyMed Link: | VISUDYNE at DailyMed |
Recent Clinical Trials for VISUDYNE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Wake Forest University Health Sciences | Phase 4 |
| Tan Tock Seng Hospital | N/A |
| National University Hospital, Singapore | N/A |
Pharmacology for VISUDYNE
| Drug Class | Photoenhancer |
| Mechanism of Action | Photoabsorption |
| Physiological Effect | Photosensitizing Activity |
US Patents and Regulatory Information for VISUDYNE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISUDYNE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch Lomb Ireland | VISUDYNE | verteporfin | INJECTABLE;INJECTION | 021119-001 | Apr 12, 2000 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for VISUDYNE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| CHEPLAPHARM Arzneimittel GmbH | Visudyne | verteporfin | EMEA/H/C/000305 Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. |
Authorised | no | no | no | 2000-07-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for VISUDYNE
See the table below for patents covering VISUDYNE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 0947222 | ⤷ Sign Up | |
| Japan | H08505069 | ⤷ Sign Up | |
| South Korea | 970007303 | ⤷ Sign Up | |
| Czech Republic | 9802789 | ⤷ Sign Up | |
| Hungary | 227978 | USE OF PORPHYRIN DERIVATIVES FOR PREPARING PHARMACEUTICAL COMPOSITIONS IMPROVING VISION | ⤷ Sign Up |
| Poland | 188888 | ⤷ Sign Up | |
| Netherlands | 300037 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISUDYNE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0352076 | 1/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: VERTEPORFIN; REGISTRATION NO/DATE: EU/1/00/140/001 20000727 |
| 0352076 | C300037 | Netherlands | ⤷ Sign Up | PRODUCT NAME: VERTEPORFINE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/00/140/001 20000727 |
| 0352076 | 2001C/010 | Belgium | ⤷ Sign Up | PRODUCT NAME: VERTEPORFIN; NAT. REGISTRATION NO./DATE: EU/1/00/140/001 20000727; FIRST REGISTRATION: CH 55269 19991215 |
| 0352076 | SPC/GB01/005 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VERTEPORFIN OPTIONALLY IN THE FORM OF A SALT THEREOF; REGISTERED: UK EU/1/00/140/001 20000727 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
